Improving Women’s Health With Randox

Randox are dedicated to improving health worldwide, Throughout the month of June we hope to highlight how the Randox clinical product range can ensure accurate and swift diagnosis and by doing so improving women’s health by allowing for the necessary steps to be taken post diagnoses. A common held misconception is that breast cancer is the biggest threat to a women’s health however the biggest health risk to a woman statistically is heart disease which accounts for roughly 27% of female death. The Randox clinical product range offers a wide range of products to combat heart issues including the RX series extensive cardiac testing panel, reagents such as H-FABP, Adiponectin an TxB Cardio and an extensive cardiac QC range available in both liquid & lyophilised format.

 

Women's Health: Reagents

Randox Reagents have the highest quality reagents on the market and a test menu comprising of over 118 assays covering over 100 disease markers. Several of these reagents will play a key role in diagnosis in woman such as Randox’s Lipoprotein (a) – Lp(a) test,   The Randox Lp(a) offers swift and accurate diagnosis of elevated circulation Lp(a) levels which is significant for woman as women have an increased risk of CVD due to elevated levels of Lp(a).  Several traditional CVD risk markers, including elevated LDL may be absent in some women, elevated Lp(a) levels may identify women at high risk of developing CVD.

Women's Health: RX series

The RX series range of clinical chemistry analysers offers the most comprehensive testing profile for assessing health in males and females. Urinary tract infections are more commonly found in women and the RX series extensive renal function panel will provide clarity  in terms of a woman’s urological health by testing for 19 separate analytes, including microalbumin. The RX series microalbumin test can detect very low levels of albumin in urine and if albumin is detected it can be an indicator of kidney injury and can result in irreversible damage. To view the full RX series test menu click here.

 

Women's Health: Quality Control

The Randox Acusera Maternal Screening quality control is the only commercially available control which covers all six analytes used during first and second trimester screening of Down’s syndrome and Spina Bifida. Instrument specific target values and ranges are provided for AFP, Inhibin A, PAPP-A, β hCG, Total hCG and Unconjugated Estriol. The inclusion of PAPP-A and Inhibin A eliminates the need to purchase additional controls at extra expense.

Women's Health: RIQAS

The RIQAS Maternal Screening EQA programme is designed to monitor the performance of screening tests used during the first and second trimester of pregnancy to assess the risk of Down’s syndrome, Spina Bifida and Trisomy 18. 100% human serum ensures commutability while the lyophilised material allows for enhanced stability. Monthly reporting allows laboratories to become aware of issues and remedy them early.

Clinical Laboratory Survey